Polymyositis is an inflammatory myopathy of skeletal muscle. Cardiac involvement in the disease was first described in 1899 but has only been studied in detail over the past 20 years. About 10–15% of all patients with polymyositis have a cardiac abnormality as their initial presenting feature, while up to 70% of all those with polymyositis will have some cardiac involvement diagnosed non-invasively during the course of their illness. These can manifest either as cardiac failure; electrocardiographic changes, including non-specific ST changes, and varying forms of AV block; myocarditis; valve disease and myocardial ischaemia in the presence of normal coronary vasculature.1

Myasthenia gravis is thought to be an autoimmune disease characterised by the presence of antibodies to the acetylcholine receptor of the motor end plate. Idiopathic forms are rarely associated with polymyositis, but a much stronger correlation exists in the presence of a thymoma, particularly in those with myocardial involvement, when anti-titin antibodies are usually present.1 However, thymoma is often less than 1 mm in size and therefore not visible on computed tomographic (CT) scanning.

We describe a 56 year old woman with polymyositis, who initially presented with myocardial involvement and was also found to have antibodies consistent with myasthenia gravis.

CASE REPORT
A 56 year old woman was admitted to this hospital for insertion of a permanent pacemaker after an episode of dizziness and collapse, secondary to complete heart block.

She had a past history of anterolateral myocardial infarction 10 months previously for which she received thrombolytic treatment in a district general hospital. Treatment was started with aspirin, atenolol, ramipril, and pravastatin after the infarction. Subsequent coronary angiography was normal. At outpatient follow up five months later, she was found to have a creatine kinase (CK) level of greater than 3000 U/l associated with significant leg weakness. Electromyographic (EMG) analysis showed changes consistent with old polio, which had affected the patient as a child. Attempts at muscle biopsy were unsuccessful. A statin-induced myositis was thought likely, and pravastatin was discontinued.

Six months later she presented in complete heart block and at the time of transfer to cardiology in this hospital for pacing, examination showed significant proximal muscle weakness with 3/5 power in both arms, and 2/5 power in the legs; distal muscle power was normal. Neurological examination demonstrated normal sensation but absent knee, bicep and ankle jerks, with bilaterally downgoing planters.

Investigations showed a CK of 22 800 U/l (CK MB fraction <0.1). The erythrocyte sedimentation rate was mildly raised at 35 mm/1st h; thyroid function was normal; and rheumatoid factor, antinuclear antibodies, antineutrophil cytoplasmic antibodies, and viral screens were negative. Echocardiography showed good LV function with trivial MR; ultrasound of the abdomen was normal; and EMG analysis again showed features consistent with previous poliomyelitis, in addition to severe myositis. Magnetic resonance imaging could not be performed because of the pacemaker. A diagnosis of polymyositis was made and treatment was started with 60 mg/day prednisolone and intravenous immunoglobulin. A muscle biopsy, after 13 days of prednisolone, showed an inflammatory infiltrate with myonecrosis consistent with inflammatory myopathy.

Anti-acetylcholine receptor antibodies and anti-titin antibodies were also positive but CT of the thorax showed no evidence of thymoma and single fibre EMG studies were not supportive of a diagnosis of myasthenia gravis.

The patient was discharged after 20 days on 55 mg/day prednisolone with repeat admissions organised for immunoglobulin every six weeks, and neurological review for her possible myasthenia gravis. Upon discharge, she had 4/5 muscle power with a CK of 1113 U/l.

Subsequent follow up two months after her initial admission showed a CK of <200 U/l and complete restoration of muscle power. She is currently receiving 35 mg/day prednisolone, reducing by 2.5 mg/month.

DISCUSSION
Our case demonstrates several of the important cardiac features in polymyositis. The initial infarction, which occurred in the presence of only two significant cardiovascular risk factors (hypertension and hypercholesterolaemia), and the subsequent normal coronary angiography suggest the presence of myocardial ischaemia with normal coronary vasculature as described previously. It is thought that the ischaemia may be related to small vessel myocardial disease, which would not be evident on angiography. However, myocardial infarction in the presence of normal coronary vasculature is not uncommon, and alternative explanations in this example include infarction with clot lysis; infarction secondary to coronary artery spasm; or myocarditis.

Fibrosis of the conducting system of the heart, particularly the AV node, has been previously characterised and might have explained the patient’s subsequent presentation in complete heart block. As there was no evidence of significant myocardial ischaemia in this patient (CK MB fraction <0.1 and only mildly raised increase in troponin), fibrosis was felt to be the most likely pathological mechanism in this instance.

Arriving at a diagnosis of myasthenia gravis in a patient with muscle inflammation is difficult, as standard investigations such as tension tests are inaccurate in the presence of pre-existing muscle weakness, and a negative EMG analysis does not necessarily dismiss the diagnosis. The presence of old polio in this patient was a further confounding factor. Equally, symptoms may be disguised by both the pre-existing polymyositis and its treatment, as immunosuppression is a well recognised treatment for both. However, anti-acetylcholine and anti-titin antibodies are highly specific, and the association between myasthenia gravis, polymyositis, and cardiac disease, particularly with microscopic thymoma, is well characterised. Although we do not feel we have enough...
Eosinophilic fasciitis with multiple myeloma: a new haematological association

D Khanna, A Verity, J M Grossman

Ososphilic fasciitis (EF) is characterised by skin induration, hypergammaglobulinaemia, and peripheral eosinophilia. There have been numerous reports of an association of EF with haematological disorders, including monoclonal gammopathy. To our knowledge, we describe the first reported case of an association of EF with multiple myeloma (MM).

CASE REPORT
A 48 year old white woman presented for evaluation of a 12 month history of progressive increasing skin thickness and tightening and recurrent falls. The patient was in her usual state of health until one year before admission when she noticed increased skin pigmentation with diffuse skin thickening, initially on the thighs but progressing to her abdomen and arms. She denied any Raynaud’s phenomenon. On examination, the vital signs were normal. Examination of the laboratory tests in myasthenia gravis. Muscle Nerve 1985;48:1246–52.

REFERENCES
clonal gammopathy has only been reported twice. Gammaglobulinaemia is a well described feature of EF, mononucleosis and myeloproliferative disorder; each of the last three conditions have been seen in one case of EF. Whereas hypergammaglobulinaemia is a well described feature of EF, monoclonal gammopathy has only been reported twice. We present the first case report of IgG\(\lambda\) MM associated with EF. The presence of monoclonal gammopathy can also be seen with scleroderma (SSc) like skin diseases including scleromyxoedema and scleredema, but the pathogenesis of these diseases is still largely unknown. Sera from patients with scleroderma and MM have been shown to stimulate collagen production, both in the normal fibroblasts and in the autologous cell cultures, suggesting that serum factors produced by the myeloma cells might have a role in the development of dermal thickening. Also, treatment of MM improves the skin involvement mimics rheumatic diseases. Arthritis Rheum 1986;29:913–17.


**Figure 1** A thickened, hyalinised amorphous tissue containing small chronic inflammatory foci replaces the fascia. The fascial-epimysial interface is replaced by dense collagen inducing compressional atrophy of adjacent muscle bundles (arrow) (x80).
Dust exposure: a missed environmental factor of Wegener’s granulomatosis

B Granel, J Serratrice, P Disdier, S Abdul, R Gras, F Martin, L Swiader, P-J Weiller

Infectious agents, genetic background, and environmental exposure as observed in this case report, are thought to play a part in Wegener’s granulomatosis (WG).1

CASE REPORT
A 54 year old man consulted in 1999 for an eight year history of bilateral crusty and bloody rhinosinusitis. He had worked from 1965 to 1980 as a ship’s carpenter. During this period he had constantly had nose pain, sore mucosal discomfort, frequent nasal bloody discharge, and chronic nasal obstruction when planing woods (iroko, oak, and ash), removing paint, and undertaking activities with dust exposure. He did not wear a mask. He had been a heavy smoker until the age of 40 and had never used cocaine. No nasal deformity was noted.

Nasal fibroscopy disclosed erythematous and inflamed mucosa of the nasal septum and inferior turbinate in the left nasal cavity. There was biological inflammation with normal kidney function. A search for antinuclear and antiphospholipid antibodies was negative and serum angiotensin converting enzyme was normal. A high titre of antineutrophil cytoplasmic antibodies (ANCA) with cytoplasmic pattern on immunofluorescence and positivity of an enzyme linked immunosorbent assay (ELISA) for antiproteinase 3 antibodies (153IU/ml, normal <2) was noted. Blood lymphocyte immunophenotyping was normal. A thoracoabdominal computed tomographic (CT) scan was normal and a sinus CT scan showed evidence of thickening of the mucous membranes of the maxillary and frontal sinuses, associated with a bilateral ethmoiditis. Endonasal biopsy showed important granulomatous inflammation in the mucosa and around the vessel walls with necrosis compatible with WG.

The patient received oral steroids (40 mg/day) and trimethoprim-sulfamethoxazole in association with four intravenous cyclophosphamide pulses (0.6 g/m² every four weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed. The oral steroid dose was 18 mg/day in weeks). One year later, the nasosinusal symptoms had almost completely regressed.

DISCUSSION
In our patient, WG was diagnosed with chronic bilateral crusty and bloody rhinosinusitis, strong positivity of cANCA, and histopathological inflammatory infiltrate with necrosis. Moreover, cases of WG in woodworkers were reported in the 1970s.1,2 The case described by Fombeur et al concerned a 23 year old man who had been a woodworker since the age of 18.3 WG affected the sinuses, lungs, and kidney.4 Grimaud et al reported another case of sinonasal WG in a 34 year old carpenter.4 He presented necrotic pseudotumours in both sinuses associated with nasal septum perforation and ulceration of the soft palate.5 The fatal outcome was due to a pneumoneral syndrome. In their experience with 12 cases of WG, Israel and Patchefsky observed one case in a black woodworker.6 Neutrophils and cANCA seem to have an active role in the pathogenesis of WG. In our case, inflammatory response to irritative dusts might have induced a chronic rhinosinusitis and later favoured a cANCA related neutrophilic activation with a granulomatous reaction. Our observation reminds us that environmental exposure may constitute an underestimated triggering factor for WG. However, as woodworkers are rare nowadays, recent publications do not mention environmental exposure, which should nevertheless be taken into account.

Authors’ affiliations
B Granel, J Serratrice, P Disdier, L Swiader, P-J Weiller, Service de Médecine Interne, Hôpital de la Timone, 264 rue Saint-Pierre, 13385 Marseille Cedex 5, France
S Abdul, R Gras, Fédération d’Oto-Rhino-Laryngologie, Hôpital de la Timone
F Martin, Service de Médecine du Travail, Hôpital de la Timone
Correspondence to: Dr P Disdier; pdisdier@ap-hm.fr
Accepted 2 May 2002

REFERENCES
Spinal cord stimulation in Buerger’s disease

A V Pace, N Saratzis, D Karokis, D Dalainas, G D Kitas

Buerger’s disease (BD) is characterised by segmental inflammation of medium and small size arteries, affects mainly young adult men, and is more prevalent in the southeast Mediterranean and the Far East. Its pathogenesis remains unclear, but cigarette smoking is strongly implicated. Autoimmune diseases, hypercoagulable states, diabetes, and emboli need exclusion before a diagnosis is made. The tibial and leg digital arteries are usually affected, and arteriography shows typically “corkscrew” peripheral obstructions. The best treatment is stopping smoking. Prostacyclin infusion is currently the most effective treatment for pain control and healing of ischaemic lesions. In selected cases, regional guanethidine block may have good results. Sympathectomy does not always provide lasting benefit, and arterial bypass is difficult due to poor run-off in the diseased arteries. Limited amputations are often necessary to remove necrotic tissue.

New methods are being tested for pain relief and ulcer healing, including pedicled omental transfer and induction of angiogenesis using vascular endothelial growth factor gene transfer. Spinal cord stimulators (SCS) are used extensively in refractory peripheral atherosclerotic disease. Experience in BD is limited but suggests that SCS have favourable effects on pain and healing of digital ulcers, comparable with those noted in other arteriopathies.

CASE REPORTS

We present our experience of the use of SCS in three patients with BD. They were all male, middle-aged smokers, who had presented with painful ischaemic ulcers of the legs at least six years earlier, had typical angiographic appearances of BD, no evidence of other relevant diseases and had been (and still are) unable to stop smoking. Over that period, they had all required repeated admission to hospital and had unsuccessfully tried various treatments to relieve pain and promote healing of their ischaemic ulcers, including analgesics, vasodilators, antiplatelet agents, epidural analgesia, prostacyclin, and local guanethidine infusions. One patient had needed amputation of gangrenous toes and another a below-knee amputation after these treatments failed. SCS were used in all three patients to manage intractable pain, poor wound healing, and recurrence of ischaemic lesions occurring postoperatively. Within four months of treatment with SCS, the pain resolved completely and the wounds healed in all three patients and they were able to return to work. One of them requires oral analgesia after prolonged periods of standing, but none of them has required further admission to hospital.

DISCUSSION

SCS may modulate painful stimuli through several mechanisms. According to the gate control theory of pain, stimulation of large diameter, type A fibres at the posterior horns of the spinal cord by low amplitude electric current inhibits simultaneous transmission of painful stimuli through the same spinal cord segment. Similarly, inhibition of sympathetic vasoconstriction improves the peripheral microcirculation. Nitric oxide and γ-aminobutyric acid systems in the spinal cord may be important intermediaries in SCS-induced pain relief. In arterial insufficiency, SCS have been shown to decrease rest pain (Fontaine class III), improve claudication distance, raise skin temperature, and increase transcutaneous oxygen tension in the foot, with values of >10 mmHg before treatment being associated with significantly better outcome.

SCS may be a useful therapeutic option in BD, particularly for pain control and wound healing and may delay the need for amputation in selected patients who have exhausted all other therapeutic options. Return to work and reduced need for repeated hospital admissions may balance the overall expense of the procedure. Further studies are required to determine the exact indications for the use of SCS in BD, while stopping smoking should continue to be emphasised as the most important treatment.

REFERENCES

8 Stanton-Hicks M, Salamon J. Stimulation of the central and peripheral nervous system for the control of pain. J Clin Neurophysiol 1997;14:46–62
Dust exposure: a missed environmental factor of Wegener's granulomatosis

B Granel, J Serratrice, P Disdier, S Abdul, R Gras, F Martin, L Swiader and P-J Weiller

Ann Rheum Dis 2002 61: 1113
doi: 10.1136/ard.61.12.1113

Updated information and services can be found at:
http://ard.bmj.com/content/61/12/1113

These include:

References

This article cites 7 articles, 1 of which you can access for free at:
http://ard.bmj.com/content/61/12/1113#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/